Literature DB >> 7828157

Hematologic, clinical, and cytogenetic analysis in 109 patients with primary myelodysplastic syndrome. Prognostic significance of morphology and chromosome findings.

V Parlier1, G van Melle, P Beris, P M Schmidt, A Tobler, E Haller, M J Bellomo.   

Abstract

One hundred and nine patients with primary myelodysplastic syndrome (MDS) were classified according to the French-American-British (FAB) criteria: 27 refractory anemia (RA, 25%), 26 RA with ringed sideroblasts (RARS, 24%), 16 RA with excess of blasts (RAEB, 15%), 10 RAEB in transformation (RAEB-t, 9%), 25 chronic myelomonocytic leukemia (CMMoL, 23%), and five unclassifiable MDS (4%). Forty-three were women and 66 were men (sex ratio 2:3). Age ranged from 30-92 years (mean 69 years) with nine patients aged less than 50 years (8%). A cytogenetic result was obtained in all cases. At initial study, a chromosome defect was observed in 56% of patients. Rates of abnormality depended on FAB subtype: 52% in RA, 100% in RA 5q-, 50% in RARS, 56% in RAEB, 70% in RAEB-t and 44% in CMMoL. The most frequent single defects were del(5q), -7/del(7q), del(20q), Y loss, and +8. Except for the 5q- syndrome entity, specific chromosome defects were not associated with particular FAB subtypes. Bone marrow (BM) insufficiency (22%) and leukemic transformation (21%) were the most important causes of death. The rate of leukemic transformation increased with the number of dysplastic BM cell lineages and was also associated with karyotype complexity and the proportion of abnormal/normal metaphases. The longest median survivals were observed in RARS (142 months) and RA/RA5q- (91 months) types. Median survivals decreased with increasing Bournemouth score values. Patients with three abnormal cell lineages had a median survival shorter than those with one or two abnormal lineages. Similarly, patients with complex defects had shorter survival than those with single or double defects or a normal karyotype. There was no statistically significant difference between survival of NN (normal), AN (abnormal/normal), and AA patients or between survival of patients with del(5q), -7/del(7q), +8 or del(20q).

Entities:  

Mesh:

Year:  1994        PMID: 7828157     DOI: 10.1016/0165-4608(94)90094-9

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  5 in total

1.  The impact of category, cytopathology and cytogenetics on development and progression of clonal and malignant myeloid transformation in inherited bone marrow failure syndromes.

Authors:  Michaela Cada; Catherin I Segbefia; Robert Klaassen; Conrad V Fernandez; Rochelle A Yanofsky; John Wu; Yves Pastore; Mariana Silva; Jeffrey H Lipton; Josee Brossard; Bruno Michon; Sharon Abish; MacGregor Steele; Roona Sinha; Mark Belletrutti; Vicky Breakey; Lawrence Jardine; Lisa Goodyear; Lillian Sung; Mary Shago; Joseph Beyene; Preeti Sharma; Bozana Zlateska; Yigal Dror
Journal:  Haematologica       Date:  2015-02-14       Impact factor: 9.941

2.  Establishment of a xenograft model of human myelodysplastic syndromes.

Authors:  Yukari Muguruma; Hiromichi Matsushita; Takashi Yahata; Shizu Yumino; Yumiko Tanaka; Hayato Miyachi; Yoshiaki Ogawa; Hiroshi Kawada; Mamoru Ito; Kiyoshi Ando
Journal:  Haematologica       Date:  2010-12-29       Impact factor: 9.941

3.  First Cytogenetic Profile of Omani Patients with de novo Myelodysplastic Syndromes: Comparison with data from Asia, Africa, Europe and North and South America.

Authors:  Achandira M Udayakumar; Nagla Fawaz; Anil Pathare; Shakila Asraf; Mohammed Al-Huneini; Khalil Al-Farsi; Salam Al-Kindi; Murtadha Al-Khabouri
Journal:  Sultan Qaboos Univ Med J       Date:  2017-10-10

4.  Clinico-Hematological and cytogenetic spectrum of adult myelodysplastic syndrome: The first retrospective cross-sectional study in Iranian patients.

Authors:  Mostafa Paridar; Kazem Zibara; Seyed Esmaeil Ahmadi; Abbas Khosravi; Maral Soleymani; Ebrahim Azizi; Omid Kiani Ghalesardi
Journal:  Mol Cytogenet       Date:  2021-05-08       Impact factor: 2.009

5.  Cytogenetic features in primary myelodysplastic syndrome Egyptian patients.

Authors:  Yasser Elnahass; Lamiaa Youssif
Journal:  J Adv Res       Date:  2018-02-07       Impact factor: 10.479

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.